List of Excipients in Branded Drug NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

Generic Drugs Containing NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

Company	Ingredient	NDC	Excipient
Sandoz Inc	nitrofurantoin (monohydrate/macrocrystals)	0185-0122	CARBOMER HOMOPOLYMER TYPE B
Sandoz Inc	nitrofurantoin (monohydrate/macrocrystals)	0185-0122	D&C YELLOW NO. 10
Sandoz Inc	nitrofurantoin (monohydrate/macrocrystals)	0185-0122	FD&C BLUE NO. 1

What are the Most Frequently-Used Excipients in NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)?

# Of NDCs	Excipient
1	ANHYDROUS LACTOSE
2	CARBOMER 934
45	CARBOMER HOMOPOLYMER TYPE B

Nitrofurantoin Monohydrate/Macrocrystals: Excipient Strategy, Patent Position and Commercial Opportunities

Last updated: August 31, 2026

Nitrofurantoin monohydrate/macrocrystals is a mature oral urinary anti-infective marketed primarily as a 100 mg modified-release capsule. The commercial opportunity is no longer based on basic molecule ownership. It depends on reliable dissolution control, bioequivalence execution, differentiated excipient selection, supply-chain efficiency, and lifecycle products that improve tolerability or administration.

The reference product, Macrobid, contains 25 mg nitrofurantoin monohydrate and 75 mg macrocrystalline nitrofurantoin per 100 mg capsule. The dual-solid-state design controls dissolution and differentiates the product from immediate-release nitrofurantoin formulations such as Macrodantin [1]. Nitrofurantoin is used mainly for treatment and prevention of uncomplicated lower urinary tract infections caused by susceptible organisms.

What formulation protects nitrofurantoin monohydrate/macrocrystals?

The core formulation protection is the combination of two nitrofurantoin physical forms rather than a conventional excipient-only delivery system.

Product characteristic	Macrobid-type formulation
Active ingredient	Nitrofurantoin
Dosage form	Oral capsule
Strength	100 mg
Solid-state composition	25 mg monohydrate plus 75 mg macrocrystals
Release profile	Modified release relative to conventional nitrofurantoin capsules
Administration	Typically taken with food
Primary therapeutic use	Acute uncomplicated cystitis
Reference product	Macrobid
Regulatory pathway for competitors	Abbreviated New Drug Application, or ANDA

The monohydrate and macrocrystalline fractions have different dissolution behavior. Macrocrystals dissolve more slowly than smaller nitrofurantoin particles, which can reduce peak exposure and improve gastrointestinal tolerability. The monohydrate fraction contributes a different dissolution component and helps produce the intended release profile.

The excipient system supports capsule manufacture, powder flow, content uniformity, lubrication, moisture control and reproducible dissolution. It is unlikely to provide meaningful protection by itself unless a sponsor develops a novel formulation with a defined performance advantage.

Which excipients are used in the reference formulation?

Public labeling identifies conventional capsule excipients, including lactose, corn starch, talc and magnesium stearate, with gelatin and coloring agents used in the capsule shell [1,2]. Exact excipient grades, particle-size distributions, processing conditions and supplier specifications can affect dissolution and manufacturing performance even when the qualitative composition is copied.

Key excipient functions include:

Excipient or excipient class	Principal function	Main development issue
Lactose	Diluent and capsule-fill bulking agent	Moisture sensitivity, patient intolerance and Maillard-related compatibility risk
Corn starch	Filler, disintegrant and powder-structure modifier	Variable swelling and flow properties
Talc	Glidant and anti-adherent	Regulatory scrutiny of mineral quality and contamination controls
Magnesium stearate	Lubricant	Over-lubrication can slow wetting and dissolution
Gelatin	Capsule shell	Moisture transfer and shell brittleness
Titanium dioxide or colorants	Appearance and product identification	Geographic regulatory restrictions for selected colorants

A generic developer should treat the reference product's dissolution profile as a critical quality attribute. Small changes in lubricant level, blending time, particle-size distribution or shell moisture can shift release behavior.

How does the excipient strategy affect bioequivalence?

Bioequivalence risk is driven more by the active-ingredient particle population and capsule performance than by excipient novelty. Nitrofurantoin has low aqueous solubility, and food affects absorption. The FDA label recommends administration with food to improve absorption and tolerability [1].

A commercially viable development program should control the following variables:

1. Nitrofurantoin crystal form and polymorphic state.
2. Ratio of monohydrate to macrocrystalline material.
3. Particle-size distribution and agglomeration.
4. Bulk density and powder-flow characteristics.
5. Capsule fill weight and blend uniformity.
6. Lubrication time and magnesium stearate distribution.
7. Dissolution across multiple pH conditions.
8. Fed-state pharmacokinetic performance.
9. Stability under moisture and temperature stress.

The principal development mistake is to treat nitrofurantoin monohydrate/macrocrystals as a routine powder-filled capsule. The active material is itself a release-controlling component. A formulation can match the labeled excipients and still fail comparative dissolution or pharmacokinetic testing if crystal size, surface area or solid-state composition differs.

What excipient changes create the lowest regulatory risk?

The lowest-risk approach is a qualitative and quantitative formulation that remains close to the reference product. This strategy minimizes the likelihood that differences in wetting, capsule rupture, dissolution or gastrointestinal transit will affect exposure.

Low-risk changes include:

• Substitution with an equivalent lactose grade.
• Use of pregelatinized or standard corn starch with demonstrated functionality.
• Optimization of magnesium stearate within a narrow range.
• Replacement of colorants where permitted, provided capsule identification remains acceptable.
• Use of equivalent hard-gelatin capsule shells with matched moisture behavior.
• Tight control of talc grade and mineral impurity profile.

Higher-risk changes include:

• Replacing lactose with mannitol or microcrystalline cellulose.
• Adding a polymeric sustained-release matrix.
• Using lipid excipients or surfactants to increase wetting.
• Converting the formulation to a multiparticulate bead system.
• Reducing or eliminating the macrocrystalline fraction.
• Introducing enteric coating.
• Using amorphous nitrofurantoin or a new salt or cocrystal.

These changes may support a differentiated 505(b)(2) product, but they increase clinical, CMC and regulatory requirements.

What commercial opportunities exist for nitrofurantoin excipients?

The strongest opportunity is not a new excipient for its own sake. It is a formulation platform that solves a specific commercial problem.

1. Lactose-free nitrofurantoin capsules

A lactose-free capsule could address hospitals, pharmacies and patients who avoid lactose. The commercial value is limited because the amount of lactose in a capsule is generally small, but a lactose-free claim can support institutional formulary positioning and international market access.

Potential replacement systems include microcrystalline cellulose, mannitol, dibasic calcium phosphate or selected starch-based blends. The formulation must preserve powder flow, fill-weight accuracy and dissolution.

The principal risk is that a new filler changes wetting or disintegration enough to alter the release profile. A lactose-free product should be evaluated against the reference under fed and fasting conditions, with emphasis on early and late dissolution intervals.

2. Gluten-free and allergen-controlled products

Nitrofurantoin capsules can be positioned for patients and institutions seeking controlled excipient profiles. A gluten-free claim requires documented raw-material controls, supplier qualification and cross-contamination management.

This is primarily a market-access and procurement opportunity rather than a strong clinical differentiation. It may be useful in countries where excipient labeling and allergen declarations influence prescription selection.

3. Sprinkle or opened-capsule administration

A capsule that can be opened and sprinkled onto soft food could improve administration for patients with dysphagia, selected elderly patients and home-care populations. The product would require evidence that:

• The capsule contents remain uniformly distributed.
• The macrocrystalline fraction does not segregate.
• The product is acceptable in the selected vehicle.
• Dose recovery is adequate.
• The stability window after opening is defined.
• The modified-release behavior is preserved.

A sprinkle product may justify a 505(b)(2) strategy if the reference labeling does not support the same administration method. It also creates intellectual-property opportunities around dose uniformity, taste masking, handling and administration instructions.

4. Pediatric and geriatric delivery systems

Nitrofurantoin is difficult to formulate as a palatable liquid because of taste, suspension stability and dose uniformity challenges. A dry suspension, dispersible granule or mini-capsule could address pediatric use, although the market is narrower than the adult cystitis market.

For geriatric use, a low-swallow-force capsule, smaller capsule size or sprinkle format may be more commercially practical than a liquid. The main technical challenge is preserving the monohydrate/macrocrystal dissolution profile after size reduction or repackaging.

5. Improved moisture and temperature stability

A capsule with improved stability can reduce waste in hot or humid markets. Potential approaches include:

• High-barrier blister packaging.
• Moisture-controlled hard capsules.
• Desiccant bottle systems.
• Low-moisture excipient grades.
• Improved raw-material packaging.
• Nitrogen-filled packaging where justified.

Packaging is often a more defensible and lower-risk intervention than changing the excipient composition. A formulation and packaging combination can support a differentiated product without changing the active ingredient.

What patents protect nitrofurantoin monohydrate/macrocrystals?

The foundational composition and use patents for nitrofurantoin and conventional oral formulations are long expired. Macrobid is a legacy product, and its commercial position is based on established regulatory approval, manufacturing know-how and market recognition rather than current molecule exclusivity.

IP category	Current commercial relevance
Nitrofurantoin compound patents	Expired
Conventional oral capsule patents	Generally expired
Macrobid-type monohydrate/macrocrystal concept	Mature technology; any original protection is expired or near-expired
Excipient-only formulation patents	Possible, but must contain a specific novel combination or performance limitation
Administration patents	Possible for sprinkle, pediatric or modified-use products
Manufacturing patents	Possible for crystal-size control, blending or particle engineering
Packaging patents	Possible but usually narrow
Trademark rights	Brand-specific and separate from patent exclusivity

Patentability is more plausible for a new process or delivery system than for simply replacing lactose with another diluent. A defensible patent claim would need to connect the excipient or process to a measurable technical result, such as:

• A specified dissolution profile.
• Reduced gastrointestinal adverse events.
• Improved crystal-size stability.
• Reduced segregation during capsule filling.
• Improved stability at elevated humidity.
• Dose uniformity after capsule opening.
• Improved palatability or administration compliance.

Are there Paragraph IV challenges to Macrobid?

Generic nitrofurantoin monohydrate/macrocrystals products have entered through the ANDA pathway, demonstrating that the reference product's principal regulatory protections do not block generic competition. Paragraph IV certifications may have been relevant during the historical generic approval process, but the central commercial issue today is post-exclusivity competition rather than an active first-wave patent challenge.

The FDA Orange Book should be checked for the current listed patents and exclusivity status associated with the reference NDA [3]. A current patent assertion or settlement should not be inferred solely from historical ANDA litigation.

What is the FDA regulatory status of nitrofurantoin monohydrate/macrocrystals?

Nitrofurantoin monohydrate/macrocrystals is an FDA-approved prescription oral capsule product. The reference product is Macrobid, marketed by the original innovator and followed by generic ANDA products [1,3].

The principal regulatory routes are:

Development objective	Likely FDA pathway
Same 100 mg capsule and release characteristics	ANDA
Lactose-free or excipient-modified equivalent	ANDA if sameness and bioequivalence requirements are met
New sprinkle administration	Potential 505(b)(2)
Pediatric liquid or dispersible product	Potential 505(b)(2)
New dosing regimen or indication	505(b)(2) or supplemental pathway, depending on the change
New crystal form or delivery technology	ANDA only if reference-product equivalence remains supportable; otherwise 505(b)(2) risk

There is no biosimilar pathway for nitrofurantoin because it is a small-molecule antibacterial, not a biologic. The relevant competitive pathways are ANDA, 505(b)(2), state substitution rules and procurement contracting.

How strong is the patent estate for nitrofurantoin monohydrate/macrocrystals?

The patent estate is weak for the basic product and potentially moderate for narrowly drafted lifecycle inventions.

A practical strength assessment is:

IP asset	Strength assessment	Commercial implication
Basic nitrofurantoin composition	Very weak due to age	No meaningful molecule-level barrier
Monohydrate/macrocrystal formulation concept	Weak to moderate depending on claim scope and expiration	Difficult to rely on for current exclusivity
New excipient combination	Moderate only with strong comparative data	Can support a narrow formulation moat
Crystal-engineering process	Moderate if difficult to design around	May protect manufacturing know-how
Sprinkle or pediatric delivery	Moderate to strong if clinically useful	Supports differentiated 505(b)(2) product
Packaging and stability system	Weak to moderate	More useful for cost and geographic access than exclusivity

Trade secrets may have greater practical value than patents for crystal processing, blending order, lubrication conditions, capsule filling and release testing. These controls can create manufacturing consistency without creating a visible Orange Book barrier.

What generic entry risks exist?

Generic entry is already a structural feature of this market. Commercial risks include:

• Price erosion from multiple ANDA suppliers.
• Pharmacy substitution.
• Hospital and group-purchasing pressure.
• Shortages caused by low-margin manufacturing.
• Dependence on qualified nitrofurantoin API suppliers.
• Variability in macrocrystal particle-size control.
• Recalls linked to dissolution, assay or content uniformity.
• Increasing regulatory scrutiny of nitrofurantoin use in renal impairment.
• Competition from other oral antibiotics for uncomplicated cystitis.

A new entrant should not assume that approval creates durable pricing power. The strongest opportunities are differentiated supply, reliable availability, institutional contracts and formulations with a clear administration or tolerability benefit.

How does nitrofurantoin compare with competing urinary anti-infectives?

Product class	Differentiation	Excipient opportunity	Competitive pressure
Nitrofurantoin monohydrate/macrocrystals	Narrow urinary distribution and established use for cystitis	Crystal control, sprinkle format, lactose-free capsule, stability packaging	High generic pressure
Fosfomycin tromethamine	Single-dose oral regimen	Palatability, sachet flow, reconstitution and taste masking	Differentiated dosing
Trimethoprim-sulfamethoxazole	Established oral tablet and suspension	Taste masking, suspension stability	Resistance and allergy limitations
Beta-lactam oral antibiotics	Broadly familiar dosage forms	Pediatric liquids and modified release	Broader competition
Fluoroquinolones	High tissue penetration but safety restrictions	Limited lifecycle value in uncomplicated cystitis	Stewardship and safety constraints

Nitrofurantoin's narrow urinary distribution can be commercially favorable when stewardship policies discourage broader-spectrum antibiotics. Its formulation opportunity is therefore concentrated in adherence, tolerability, administration and supply reliability rather than expanded systemic indications.

What manufacturing and IP barriers affect commercial entry?

The most important manufacturing barrier is control of the active ingredient's physical properties. A sponsor must qualify nitrofurantoin material with consistent monohydrate content, crystal morphology, particle-size distribution and bulk handling behavior.

Critical process controls include:

• Milling or classification conditions.
• Environmental humidity during blending.
• Order of excipient addition.
• Blend time and shear exposure.
• Lubrication endpoint.
• Capsule-fill weight control.
• In-process segregation testing.
• Dissolution sampling and method robustness.
• Stability testing in commercial packaging.

Geographic coverage is generally straightforward because nitrofurantoin is an established small molecule and does not require biologic cold-chain infrastructure. The main geographic differences involve excipient acceptability, capsule-shell requirements, colorant restrictions, nitrosamine and elemental impurity controls, pharmacopoeial standards, and local registration data.

What licensing opportunities exist?

Licensing opportunities are more likely to involve manufacturing, geographic commercialization or differentiated delivery than ownership of the active ingredient.

Potential deal structures include:

1. Regional licensing of an approved generic capsule.
2. Contract manufacturing with guaranteed supply and dual-source API qualification.
3. Co-development of a lactose-free or sprinkle formulation.
4. Licensing of a pediatric dispersible product.
5. Acquisition of an ANDA with an established supply history.
6. Technology transfer for crystal-size and dissolution control.
7. Private-label supply to pharmacy chains and institutional buyers.

A licensee should assess the ANDA's approval status, manufacturing site history, warning letters, product-specific dissolution data, API source redundancy, recalls and commercial net pricing before assigning value to the product.

Key Takeaways

• Nitrofurantoin monohydrate/macrocrystals is a mature, genericized oral anti-infective.
• The formulation's key technology is the combination of 25% monohydrate and 75% macrocrystalline nitrofurantoin in the 100 mg capsule.
• Excipients control manufacturability and dissolution but do not normally create meaningful protection without a measurable technical advantage.
• Lactose-free capsules, sprinkle administration, pediatric formats and improved moisture stability are the clearest lifecycle opportunities.
• The basic patent estate is weak because the product and formulation technology are old.
• Trade secrets covering crystal processing, blending and dissolution control may be more valuable than broad formulation patents.
• There is no biosimilar risk; competition comes from ANDA generics and alternative urinary antibiotics.
• Commercial success depends on supply reliability, low-cost manufacturing, institutional contracting and differentiated administration.
• FDA Orange Book review remains necessary for any current patent, exclusivity or litigation conclusion [3].

FAQs

Can nitrofurantoin monohydrate/macrocrystals be formulated without lactose?

Yes. Lactose can be replaced with another pharmaceutically acceptable filler, but the sponsor must demonstrate acceptable content uniformity, stability, dissolution and bioequivalence. A lactose-free claim is more commercially useful than legally powerful.

Is a new nitrofurantoin crystal form patentable?

Potentially. Patentability depends on novelty, non-obviousness, reproducibility and a defined technical benefit. A new crystal form that only duplicates the reference product's dissolution and exposure profile may face a weak commercial position.

Does nitrofurantoin require a modified-release polymer?

No. The monohydrate and macrocrystalline active fractions provide the principal dissolution differentiation. Adding a polymer may increase development and regulatory risk without improving the product.

Can a nitrofurantoin capsule be opened and sprinkled on food?

The reference labeling should control current administration instructions. A sponsor seeking a labeled sprinkle indication would need product-specific compatibility, dose-recovery, stability and bioequivalence support.

What is the highest-value excipient opportunity for nitrofurantoin?

A formulation that preserves the reference dissolution profile while enabling lactose-free, dysphagia-friendly or pediatric administration has the strongest practical value. A conventional excipient substitution alone is unlikely to support durable pricing power.

References

1. U.S. Food and Drug Administration. (2023). Macrobid (nitrofurantoin monohydrate/macrocrystals) capsule: Prescribing information. FDA.

2. National Library of Medicine. (2024). DailyMed: Macrobid - nitrofurantoin monohydrate/macrocrystals capsule. U.S. National Library of Medicine.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.